Keiretsu Capital — Full Portfolio
13 tracked investments · listed companies and verified rows first
Cloud ComputingCybersecurityEnterprise SoftwareFintechSaaSBoulder, US
Co-investorsBCF VenturesNext Frontier CapitalTechstarsRockies Venture Club
CoreView provides management, security, and compliance tools for Microsoft 365 environments, enabling organizations to build resilience against attacks, manage multi-tenant complexity, enforce governance policies, and automate administrative tasks.
Cloud ComputingCybersecurityEnterprise SoftwareSaaS
Co-investorsNext Frontier CapitalRockies Venture ClubTechstars
Blaze Bioscience is a biotechnology company developing fluorescence imaging agents that let surgeons see cancer tissue in real time during surgery.
BiotechHealthtechMedical DevicesSeattle, US
James M. Olson(Director)Steven R. Daly(Executive Officer, Director)inLudmila R. Lobanova(Executive Officer)Julia Novak(Executive Officer)Heather L. Franklin(Director)Dennis M Miller(Executive Officer)
Co-investorsKeiretsu Forum
CurvaFix develops the CurvaFix Low Profile intramedullary nailing system, curved implants for surgical stabilization of pelvic fractures.
HardwareHealthtechMedical DevicesBellevue, US
Jeffrey Poole(Executive Officer)Mark Foster(Executive Officer, Director)inSteven Dimmer(Executive Officer, Director, Promoter)Dong-Gun Kim(Director)
BoardEric Fritz(Director)inJack Tanaka(Director)in
Co-investorsAlliance of AngelsArieal Southeast Angel PartnersRockies Venture ClubSPRINGROCK VENTURESSwan Venture FundMVM Life Science Partners+2 more
Clinical-stage specialty pharma developing a combination drug to treat a range of addictions, licensed from LSU Health Sciences Center.
BiotechSudbury, US
Robert B. Linke(Executive Officer, Director)
BoardRoss Barrett(Director)Franz Hefti(Director)John Beaird(Director)Joseph Lovett(Director)
Co-investorsInnovation CatalystKeiretsu ForumLouisiana Funds
Eternatear develops diagnostic and therapeutic products for dry eye disease, particularly targeting Meibomian Gland Dysfunction.
BiotechHealthtechMedical DevicesRaleigh, US
Timothy Willis(Chief Executive Officer & Chairman of the Board)Kent Geer(Chief Financial Officer & Secretary)Tim Willis(CEO, Chairman of the Board)Ralph Stone(Chief Technology Officer)Joe Huber(Chief Operating Officer)Diethart Reichardt(Chief Marketing Officer & Board Director)
Co-investorsArieal Southeast Angel PartnersCharlotte Angel FundDuke Capital PartnersKleinmuntz AssociatesBand of AngelsCarolina Angel Network+2 more
INDIGO Biosciences is a life sciences company led by professionals with expertise in life sciences, business management, and operations.
AI & Machine LearningBiotechDeep TechMedical DevicesState College, US
Dr. Jack Vanden Heuvel(Chief Scientific Officer, Co-founder)inDr. Blake Peterson(Co-founder)Fred Marroni(President & Chief Executive Officer)in
Co-investorsBroad Street AngelsiNetworksLife Sciences Greenhouse Investments
LumiThera develops the Valeda Light Delivery System, an FDA-authorized photobiomodulation (PBM) device that applies multiple light wavelengths to treat early and intermediate dry age-related macular degeneration (AMD).
BiotechHealthtechMedical DevicesPoulsbo, US
Tracy Puckett(Executive Officer)Clark Tedford(Executive Officer, Director)inScott Bradley(Executive Officer)inDuane Morrison(Executive Officer)inCindy Croissant(Executive Officer)Ryan Montecucco(Executive Officer)
Co-investors3E Bioventures CapitalEFung CapitalKeiretsu ForumLife Sciences Greenhouse InvestmentsImagine Ventures
OtoNexus Medical Technologies is developing an ultrasound-based otoscope (Novoscope) that uses a miniaturized sensor in a single-use ear speculum tip to give clinicians objective, point-of-care data on middle-ear fluid and infection type.
AI & Machine LearningDigital HealthHardwareHealthtechMedical DevicesSeattle, US
Caitlin Cameron(Chair & CEO)in
Co-investorsGolden SeedsCatalytic Impact FoundationDellin InvestmentsFarvatn VentureKeiretsu ForumMindshift Capital+5 more
Co-investorsKeiretsu Forum
Albany, US
Carlo Morgantini(Executive Officer, Director)Benjamin Cooley(Director and Chief Executive Officer of the Issuer.)
Co-investorsKeiretsu Forum
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

































